Archive for the 'In study sweden' Category
04-26-2008
In study sweden Ships Green, in Port and at Sea.
Avodart, GSK’s reductase inhibitor ARI, is the only dual acting ARI, in combination with tamsulosin, a widely prescribed a blocker, for the treatment of patients with moderate to severe benign prostatic hyperplasia BPH symptoms. The approval was based on positive two year results from the ongoing Combination of Avodart and Tamsulosin CombAT study, which showed that combination therapy with dutasteride and tamsulosin provides significantly superior and sustained improvements over two years in symptoms, peak urinary flow Qmax and quality of life versus either monotherapy, in men with moderate to severe BPH symptoms. A Digital Newspaper That Reads Like The Real Thing. Lilja and his group have previously shown that a single PSA Jalalabad afghanistan at or before age is a strong predictor of prostate cancer CaP occurring up to years later.
Posted by pepe1 in In study sweden | No Comments »